House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Crohn’s Disease in Adults

ACG · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

Selected ACG recommendations for adults with Crohn’s disease, linking objective diagnosis and monitoring to induction, maintenance and management of complications. Treatment depends on location, inflammatory activity, progression risk and previous exposure; symptom relief alone is not the treatment target. The guidance supports timely advanced therapy and coordinated medical–surgical care.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm inflammation and define disease extent

  • Assess suspected Crohn’s disease with ileocolonoscopy and biopsies, documenting extent and severity, including uninvolved mucosa. Initial tests should assess inflammation, anaemia, dehydration and malnutrition; active symptoms also warrant stool pathogen and C. difficile testing. [1]
  • Faecal calprotectin helps distinguish inflammatory from noninflammatory colonic disease; ACG recommends a cutoff in the >50–100 μg/g range (strong, moderate-certainty evidence). It supports assessment rather than independently establishing Crohn’s disease. [1]
  • Include small-bowel imaging in initial assessment. Prefer MR enterography in people younger than 35 or likely to require repeated imaging. With obstructive symptoms, obtain small-bowel imaging and/or a patency capsule before video capsule endoscopy to reduce retention risk. [1]
  • Use periodic endoscopy or cross-sectional imaging to assess inflammation rather than symptoms alone. Endoscopic mucosal healing is a treatment goal and objective activity scores can track response. [1]
  • Counsel active smokers to stop; smoking worsens activity and recurrence. Assess stress, anxiety and depression as part of care. View routine NSAID use cautiously because it may exacerbate disease. [1]

Mild disease and corticosteroid limits

  • Do not use oral mesalamine to induce or maintain remission in mildly to moderately active Crohn’s disease (strong, moderate-certainty evidence). Antibiotics are not primary treatment for luminal inflammatory disease. [1]
  • For mildly to moderately active ileocaecal Crohn’s disease, recommend controlled ileal-release budesonide 9 mg daily to induce symptomatic remission (strong, moderate-certainty evidence). Do not use it for maintenance (strong, low-certainty evidence). [1]
  • Selected adults with mild disease and low progression risk may use dietary strategies with careful monitoring. Some asymptomatic mild disease can be observed without maintenance medication, but routine follow-up must detect worsening inflammation or progression. [1]
  • Oral corticosteroids are recommended only for short-term induction in moderately to severely active Crohn’s disease (strong, low-certainty evidence). They do not maintain remission; introduce steroid-sparing treatment and taper off rather than allowing repeated or prolonged exposure. [1]

Distinguish maintenance immunomodulation from induction

  • Do not use azathioprine or mercaptopurine to induce remission in moderately to severely active disease (strong, moderate certainty). They may maintain corticosteroid-induced remission (conditional, low certainty). Check TPMT before first use and consider available NUDT15 testing; toxicity and longer-term cancer risks require individual assessment. [1]
  • After corticosteroid-induced remission of moderately to severely active Crohn’s disease, intramuscular or subcutaneous methotrexate up to 25 mg once weekly is a conditional maintenance option (moderate certainty). Monitor blood counts and liver chemistry; women capable of pregnancy require highly effective contraception. [1]

Select advanced therapy with prior treatment and safety in view

  • Do not require failure of conventional therapy before starting advanced therapy when appropriate for Crohn’s disease (conditional, low-certainty recommendation). Choose induction and maintenance strategies according to severity and progression risk. [1]
  • Anti-TNF agents—intravenous infliximab, subcutaneous adalimumab or certolizumab pegol—are recommended for induction and maintenance in moderately to severely active disease. For patients naive to both agents, intravenous infliximab plus a thiopurine is preferred over either alone. Both are strong recommendations with moderate certainty. [1]
  • Intravenous vedolizumab and ustekinumab are recommended induction and maintenance options for moderately to severely active Crohn’s disease (strong, moderate certainty). These are alternatives requiring individual selection, not a recommendation to combine them. [1]
  • Risankizumab, mirikizumab and guselkumab are recommended for moderately to severely active Crohn’s disease induction and maintenance (strong, moderate certainty). Guselkumab may use intravenous induction followed by subcutaneous maintenance, or subcutaneous induction and maintenance. After prior anti-TNF exposure, risankizumab is conditionally favoured over ustekinumab (low certainty). [1]
  • Upadacitinib is recommended for induction and maintenance of moderately to severely active Crohn’s disease after previous anti-TNF exposure (strong, moderate certainty). Assess individual risks and monitor carefully; the guideline’s treatment sequence reflects US regulatory context. [1]
  • Before anti-TNF therapy, screen for active and latent tuberculosis and assess exposure risk. Before most advanced therapies, screen hepatitis B with HBsAg, anti-HBc and anti-HBs; vaccinate seronegative patients, ideally beforehand. HBsAg-positive patients require antiviral prophylaxis before biologic therapy. Anti-HBc-positive, HBsAg-negative patients need HBV DNA assessment for reactivation risk, with periodic HBV DNA and liver chemistry monitoring. [1]

Fistulas, strictures and abscesses

  • Before advanced therapy for perianal fistulising Crohn’s disease, drain perianal abscesses and place drainage setons appropriately. Coordinate medical and surgical assessment; control sepsis before immunosuppression. [1]
  • For perianal fistulising Crohn’s disease, infliximab induction is strongly recommended (moderate certainty); adalimumab is conditionally suggested (low certainty). Antibiotics added to either may improve response (conditional, very low certainty). [1]
  • Assess symptomatic strictures clinically, radiologically and endoscopically. Active inflammatory strictures may respond to advanced therapy; predominantly fibrostenotic disease may benefit from endoscopic dilatation or surgery. [1]
  • For a Crohn’s-related intra-abdominal abscess larger than 2 cm, conditionally suggest antibiotics plus radiological or surgical drainage, withholding immunosuppression until drainage is achieved (low certainty). Most benefit from subsequent resection, although selected patients may respond to medical treatment after drainage. [1]

Follow-up after surgery and colorectal surveillance

  • After surgically induced remission, perform endoscopic assessment at 6–12 months (conditional, moderate certainty). Continued observation rather than immediate medication may be appropriate for low-risk postoperative recurrence (conditional, very low certainty); this still requires monitoring. [1]
  • For high-risk postoperative Crohn’s recurrence, anti-TNF prophylaxis is strongly recommended (moderate certainty), while vedolizumab is a conditional option (low certainty). Major risk factors include active smoking, penetrating disease and at least 2 prior surgeries. [1]
  • Recommend endoscopic colorectal-cancer surveillance for Crohn’s colitis (strong, moderate certainty). The narrative suggests starting after at least 8 years when more than 30% of the colon is involved; associated primary sclerosing cholangitis warrants surveillance at diagnosis regardless of distribution. [1]

Limitations and use

  • This is a selected adult pathway, not the complete induction, maintenance, dose-optimisation or postoperative treatment algorithm. It does not replace drug-specific contraindication, vaccination, pregnancy or laboratory-monitoring protocols.
  • Drug availability and the regulatory sequence described in this US guideline may differ in India. Tuberculosis and hepatitis B assessment are particularly relevant before immunosuppression.
  • A surgical or drainage assessment is essential for penetrating or obstructive complications; recommendations for uncomplicated luminal inflammation should not be applied automatically to those presentations.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Crohn’s Disease in Adults

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ACG
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm inflammation and define disease extent
  • Mild disease and corticosteroid limits
  • Distinguish maintenance immunomodulation from induction
  • Select advanced therapy with prior treatment and safety in view
  • Fistulas, strictures and abscesses
  • Follow-up after surgery and colorectal surveillance
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House